Metabolic syndrome: Difference between revisions
No edit summary |
|||
| (23 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
==Background== | |||
- | *Prothrombotic, proimflammatory state | ||
*May be associated with elevated CRP, IL-6, and tissue plasminogen activator, which may be associated with increased risk of cardiovascular disease and type 2 diabetes | |||
* | **Markers not shown to be of utility in the ED | ||
* | |||
* | ==Clinical Features== | ||
''Although several diagnostic features exist, below is the most widely accepted: The National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III)'' | |||
*'''Diagnostic Criteria''' - 3 or more of the following: | |||
**Waist circumference >/=102 cm in men or >/=88 cm in women | |||
**Plus 3 of the following: | |||
**Fasting blood glucose >/= to 100 mg/dL or requiring treatment for elevated blood glucose | |||
**HDL </=40 in men or </=50 in women | |||
**TGs >/=150 mg/dL | |||
**BP >/= 130/85 or requiring drug treatment for HTN | |||
==Differential Diagnosis== | |||
*[[Hypertension]] | |||
*Hyperlipidemia | |||
*[[Hyperglycemia]] | |||
*[[Hypothyroidism]] | |||
*Obstructive Sleep Apnea | |||
*Type 2 [[DM]] | |||
*[[Pheochromocytoma]] | |||
*Glucagonoma | |||
==Evaluation== | |||
* | *Not an ED diagnosis! | ||
* | *Evaluate for sequelae of associated diseases (e.g. cardiovascular disease, DM) as appropriate | ||
* | *Non-ED workup may include: | ||
* | **BMP | ||
**HbA1c | |||
**Lipid panel | |||
**TSH | |||
**+/- Polysomnography to evaluate for OSA | |||
==Management== | |||
*Lifestyle modification | |||
*[[Metformin]] | |||
*BP control(e.g. [[ACEi]] or ARBs} | |||
*OSA treatment | |||
*Depending on the level of obesity, and severity of the condition bariatric surgery may be advantageous to the patient | |||
*Possible referral to obesity management clinic | |||
==Disposition== | |||
*Discharge with outpatient follow-up | |||
==External Links== | |||
==References== | |||
<references/> | |||
[[Category:Endocrinology]] | [[Category:Endocrinology]] | ||
Latest revision as of 07:24, 18 August 2022
Background
- Prothrombotic, proimflammatory state
- May be associated with elevated CRP, IL-6, and tissue plasminogen activator, which may be associated with increased risk of cardiovascular disease and type 2 diabetes
- Markers not shown to be of utility in the ED
Clinical Features
Although several diagnostic features exist, below is the most widely accepted: The National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III)
- Diagnostic Criteria - 3 or more of the following:
- Waist circumference >/=102 cm in men or >/=88 cm in women
- Plus 3 of the following:
- Fasting blood glucose >/= to 100 mg/dL or requiring treatment for elevated blood glucose
- HDL </=40 in men or </=50 in women
- TGs >/=150 mg/dL
- BP >/= 130/85 or requiring drug treatment for HTN
Differential Diagnosis
- Hypertension
- Hyperlipidemia
- Hyperglycemia
- Hypothyroidism
- Obstructive Sleep Apnea
- Type 2 DM
- Pheochromocytoma
- Glucagonoma
Evaluation
- Not an ED diagnosis!
- Evaluate for sequelae of associated diseases (e.g. cardiovascular disease, DM) as appropriate
- Non-ED workup may include:
- BMP
- HbA1c
- Lipid panel
- TSH
- +/- Polysomnography to evaluate for OSA
Management
- Lifestyle modification
- Metformin
- BP control(e.g. ACEi or ARBs}
- OSA treatment
- Depending on the level of obesity, and severity of the condition bariatric surgery may be advantageous to the patient
- Possible referral to obesity management clinic
Disposition
- Discharge with outpatient follow-up
